丙咪嗪,临床注释-2,变异和临床注释数据

id	等位基因	注释文本
727	*17	The CYP2C1917 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C1917 allele in combination with a normal or increased function allele may have increased metabolism of imipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
726	*3	The CYP2C193 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C193 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
725	*2	The CYP2C192 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C192 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.
724	*1	The CYP2C191 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C191 allele in combination with another normal function allele may have increased metabolism of imipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of imipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

等位基因

注释文本

The CYP2C19*17 allele is assigned as an increased function allele by CPIC. Patients carrying the CYP2C19*17 allele in combination with a normal or increased function allele may have increased metabolism of imipramine as compared to patients with two normal function alleles. Patients carrying the CYP2C19*17 allele in combination with a no or decreased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

726

The CYP2C19*3 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*3 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

725

The CYP2C19*2 allele is assigned as a no function allele by CPIC. Patients carrying the CYP2C19*2 allele in combination with a no, decreased, normal, or increased function allele may have decreased metabolism of imipramine as compared to patients with two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

724

The CYP2C19*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have increased metabolism of imipramine as compared to patients with a no or decreased function allele in combination with a normal or increased function allele or with two no or decreased function alleles. Patients carrying the CYP2C19*1 allele in combination with another normal function allele may have decreased metabolism of imipramine as compared to patients with a normal function allele in combination with an increased function allele or two increased function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C19 and imipramine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of imipramine.

id	证据的ID	总结
342	1446902544	CYP2C19 2/2 + 2/3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 1/1.
341	1446902041	CYP2C19 2 is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 1/*1.
340	1183622781	CYP2C19 2/3 + 2/2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 1/1.
339	1183622249	CYP2C19 1/17 + 17/17 is associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to CYP2C19 1/1.
338	1446905415	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.
337	1446902590	CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.
336	1446902332	CYP2C19 poor metabolizers are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.
335	1183684391	CYP2C19 poor metabolizers are associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.
334	1183684364	CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.
333	PA166104954	Annotation of DPWG Guideline for imipramine and CYP2C19
332	PA166104999	Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6

证据的ID

总结

342

1446902544

CYP2C19 *2/*2 + *2/*3 are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.

341

1446902041

CYP2C19 *2 is associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.

340

1183622781

CYP2C19 *2/*3 + *2/*2 are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 *1/*1.

339

1183622249

CYP2C19 *1/*17 + *17/*17 is associated with decreased dose-corrected plasma concentrations of imipramine in people with Depressive Disorder as compared to CYP2C19 *1/*1.

338

1446905415

CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.

337

1446902590

CYP2C19 poor metabolizers are associated with decreased metabolism of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.

336

1446902332

CYP2C19 poor metabolizers are associated with increased concentrations of imipramine in people with Depressive Disorder, Major as compared to CYP2C19 normal metabolizers.

335

1183684391

CYP2C19 poor metabolizers are associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.

334

1183684364

CYP2C19 poor metabolizers is associated with decreased clearance of imipramine in healthy individuals as compared to CYP2C19 normal metabolizers.

333

PA166104954

Annotation of DPWG Guideline for imipramine and CYP2C19

332

PA166104999

Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6

id	类型	评论
1008	Update	Added DPWG guideline.
1007	Update	CA score added as part of scoring system release. LOE assigned following curator review.
1006	Update	changed to 1A because drug has CPIC recommendation

类型

1008

Update

Added DPWG guideline.

1007

Update

CA score added as part of scoring system release. LOE assigned following curator review.

1006

Update

changed to 1A because drug has CPIC recommendation